aTyr Pharma (NASDAQ:LIFE) Trading 5.7% Higher
aTyr Pharma Inc (NASDAQ:LIFE) shares traded up 5.7% on Thursday . The stock traded as high as $5.30 and last traded at $5.15, 248,731 shares traded hands during mid-day trading. An increase of 527% from the average session volume of 39,639 shares. The stock had previously closed at $4.87.
Several equities research analysts have recently weighed in on the stock. ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Zacks Investment Research cut shares of IQIYI from a “hold” rating to a “sell” rating in a research report on Friday, March 29th. Finally, William Blair reissued a “market perform” rating on shares of aTyr Pharma in a research report on Tuesday, March 26th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. aTyr Pharma presently has an average rating of “Buy” and a consensus price target of $14.18.
The stock’s 50-day moving average is $1.42. The company has a debt-to-equity ratio of 0.31, a quick ratio of 4.00 and a current ratio of 4.00. The stock has a market capitalization of $16.53 million, a P/E ratio of -0.32 and a beta of 2.35.
aTyr Pharma Company Profile (NASDAQ:LIFE)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.